TOBRAMYCIN INJECTION 40 MG
TOBRAMYCIN (TOBRAMYCIN SULFATE) : 40 MG · DIN 02230640 · FRESENIUS KABI CANADA LTD
Health Canada status: MARKETED
What is TOBRAMYCIN INJECTION?
TOBRAMYCIN INJECTION 40 MG contains TOBRAMYCIN (TOBRAMYCIN SULFATE) : 40 MG. It is listed in the Health Canada Drug Product Database under DIN 02230640, held by FRESENIUS KABI CANADA LTD, supplied as SOLUTION for INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 21-Aug-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TOBRAMYCIN INJECTION used for?
Treatment of septicemia, complicated/recurrent UTI, lower respiratory infections, serious skin/soft tissue infections (burns, peritonitis), and CNS infections caused by susceptible organisms.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02230640 |
|---|---|
| Brand name | TOBRAMYCIN INJECTION |
| Generic / active ingredient | TOBRAMYCIN (TOBRAMYCIN SULFATE) : 40 MG |
| Manufacturer | FRESENIUS KABI CANADA LTD |
| Strength | 40 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS ; INTRAMUSCULAR |
| Schedule | Prescription |
| ATC code | J01GB01 TOBRAMYCIN |
| AHFS class | 08:12.02 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 21-Aug-2026 |
| Original market date | 1997-05-05 00:00:00 |
How is it administered?
Adults: 1 mg/kg q8h (3 mg/kg/day). Life-threatening: up to 5 mg/kg/day. Children: 6-7.5 mg/kg/day in 3-4 doses. Neonates: up to 4 mg/kg/day in 2 doses. Administer IM or IV (infuse over 20-60 min).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Injection: 15-30°C. Discard 28 days after puncture. For Injection (powder): Below 30°C. Reconstituted solution: 8 hours. Diluted IV solution: 24h (room temp) or 36h (refrigerated).
How is it supplied?
10 mg/mL: 2 mL vials (25s). 40 mg/mL: 2 mL, 4 mL (25s), and 30 mL (10s) vials. 1.2 g/vial: 50 mL Pharmacy Bulk Vial (6s).
Contraindications
Known hypersensitivity to tobramycin or any other aminoglycoside. Cross-allergenicity to other aminoglycosides has been established.
Warnings and precautions
Potential for ototoxicity (vestibular/auditory) and nephrotoxicity. Monitor renal and eighth-nerve function. Contains sodium bisulfite. Clostridium difficile-associated disease (CDAD) reported.
Is TOBRAMYCIN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by FRESENIUS KABI CANADA LTD, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01GB01 TOBRAMYCIN. 9 of 23 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| TEVA-TOBRAMYCIN | 60 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02389622 |
| TOBI | 300 MG / 5 ML | SOLUTION | BGP PHARMA ULC | MARKETED | DIN 02239630 |
| TOBI PODHALER | 28 MG | CAPSULE | BGP PHARMA ULC | MARKETED | DIN 02365154 |
| TOBRAMYCIN FOR INJECTION | 1.2 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 00533688 |
| TOBRAMYCIN INJECTION USP | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02241209 |
| TOBRAMYCIN INJECTION USP | 40 MG | SOLUTION | STERIMAX INC | MARKETED | DIN 02502372 |
| TOBRAMYCIN INJECTION USP | 40 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02241210 |
| TOBRAMYCIN INJECTION USP | 40 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02533103 |
| AJ-TOBRAMYCIN | 40 MG | LIQUID | AGILA JAMP CANADA INC | CANCELLED PRE MARKET | DIN 02384930 |
| JAMP-TOBRAMYCIN | 40 MG | SOLUTION | JAMP PHARMA CORPORATION | CANCELLED POST MARKET | DIN 02420287 |
Who else supplies TOBRAMYCIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TOBRAMYCIN appears in 85 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.